ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 164

The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants

Kaiyu Jiang 1, Yungki Park 2, tao liu 3, Marc Sudman 4, Susan Thompson 5 and James Jarvis6, 1University at Buffalo, Buffalo, 2University at Buffalo Jacobs School of Medicine & Biomedical Sciences, Buffalo, 3Roswell Park Cancer Institute, Buffalo, 4Cincinnati Children's Hospital Medical Center, Cincinnati, 5Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, 6University at Buffalo Jacobs School of Medicine, Buffalo

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: genetics, Genome, juvenile idiopathic arthritis (JIA)

  • Tweet
  • Email
  • Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Title: Poster Session 3

Session Type: ACR Abstract Session

Session Time: 4:15PM-5:15PM

Background/Purpose: The JIA risk haplotypes, like those of other autoimmune diseases, are highly enriched for H3K4me1/H3K27ac histone marks, epigenetic features typically associated with functional enhancers. However, enhancer function cannot be assumed based on chromatin features alone, but must be demonstrated experimentally. Furthermore, the presence of a functional enhancer on a risk haplotype is not prima facieevidence that the enhancer plays a role in genetic risk. We therefore used in vitro reporter assays to query 2 JIA risk haplotypes, IL2RAand IL6R, to confirm the presence of functional enhancers in select H3K4me1/H3K27ac marked regions and determine the effects of JIA-associated genetic variants on enhancer function.

Methods: We used the pGL4 reporter system to query enhancer effects across a 1,000 bp region within the first intron of the IL2RAgene and a 2,483 bp intergenic region upstream of the IL6R transcription start site.  SNPs within both of these regions are in strong linkage disequilibrium (LD) with the tag SNPs that identify these JIA risk loci.  The pGL4 vector contains a minimal SV40 promoter that is, by itself, inefficient at driving luciferase function. We tiled three ~500 bp constructs across the regions of interest and cloned these constructs into pGL4 vectors, which were then transfected into Jurkat T cells.  Cells were incubated for 24 hr, after which we assessed luciferase production.  We repeated these same experiments using constructs containing genetic variants within theIL2RAintronic enhancer (rs117119468 C- >T and rs12722502 C- >T) that we identified in children with JIA using whole genome sequencing. We also tested the effects of 4 variants on the IL6Rhaplotype: rs540546266 (C >T), rs532200576 (T >C), rs9651053 (G >A), and rs540215820 (C >T).

Results: Within the H3K4me1/H3K27ac-marked regions that we queried, within the first we observed enhancer activity across a 657 bp region (chr10:6092661-chr10:6093317) within the first intron of IL2RAand in a 1,474 bp intergenic region upstream of the IL6Rgene region in Jurkat T cells. The IL2RA enhancer increased luciferase activity by 5-8 fold (compared with a control vector that contained only the minimal SV40 promoter and the luciferase gene) and the IL6R enhancer increased activity by 3-5 fold. A construct carrying a sequence within the first intron of the IL2RAgene that was not marked by the H3K4me1/H23K27ac histone signature showed no enhancement of luciferase expression compared to background. Constructs containing the JIA-associated rs117119468 C- >T allele abolished the enhancer activity within the IL2RAlocus, while the construct containing the rs12722502 C- >T allele reduced luciferase activity by 30% (p< 0.05).  In contrast, all 4 SNPs within the IL6Rlocus increased enhancer activity (p< 0.03) by 25-30%.

Conclusion: The JIA-associated risk loci, IL2RA and IL6R , contain enhancers that is are active in lymphoid cells. JIA-associated genetic variants identified by WGS and/or conventional genotyping alter enhancer activity at these loci. These findings represent conclusive evidence for the presence of non-coding, functional elements within JIA risk loci and demonstrate that JIA-associated genetic variants alter these functions.


Disclosure: K. Jiang, None; Y. Park, None; t. liu, None; M. Sudman, None; S. Thompson, None; J. Jarvis, None.

To cite this abstract in AMA style:

Jiang K, Park Y, liu t, Sudman M, Thompson S, Jarvis J. The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/the-juvenile-idiopathic-arthritis-associated-il2ra-and-il6r-haplotypes-contain-enhancers-whose-functions-are-altered-by-jia-associated-genetic-variants/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-juvenile-idiopathic-arthritis-associated-il2ra-and-il6r-haplotypes-contain-enhancers-whose-functions-are-altered-by-jia-associated-genetic-variants/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology